Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.
As of AprilMay 20172018, Indee Labs had accumulated more than USD$4.45.4 million dollars in angel, venture and non-dilutive capital.
In March ofMay 20172018, Indee Labs kickedclosed offout a seed round resulting in USD$3M2.6M in angel and venture financing from JudeFounders GomilaFund, Shaun Maguire,Main YSequence CombinatorVentures, Social+Capital, Main Sequence Ventures and Founders Fundalso among others inclusive of refunds under an Overseas Finding for Australia's R&D Tax Incentive.
43.5% of eligible R&D expenditureAUD$502,050